Compare Roundhill Magnificent Seven ETF (MAGS) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Moderna, Inc. — how do they compare? Roundhill Magnificent Seven ETF trades at $67.84, while Moderna, Inc. trades at $63.76 (market cap $24.18B). The key difference: Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MAGS | MRNA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.94 | $81.80 |
52-Week Low | $55.39 | $22.36 |
Market Cap | — | $24.18B |
Enterprise Value | — | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS trades at $67.95, down 1.58% today, with technical indicators showing a bullish moving average trend but overbought RSI levels. The ETF holds equal-weighted exposure to the Magnificent Seven tech stocks, which have underperformed the broader market this year amid shifting investor focus toward semiconductors and AI infrastructure. Recent news highlights concerns over aggressive AI capital spending pressuring dividends and buybacks.
The outlook remains cautious as AI profit realization lags expectations, though hyperscaler valuations are compressed. Key risks include concentration in tech, high expectations, and macroeconomic sensitivity. Analyst sentiment is mixed, with some seeing long-term AI potential but near-term headwinds from earnings pressure and market rotation.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
